$BMOD: Moving Up The Ranks
March 23rd, 2010 at 9:48 am Posted by
$BMOD caught The Dean’s attention because this stock is listed as the second most searched stock on BoardCentral.com, with an 11500% increase in searches today.
Biomoda, Inc. (OTC: BMOD.OB) is a development stage company engaged in the research, development, production, and marketing of medical and biomedical products.
As an in-vitro diagnostics company, $BMOD develops tests to detect cancer. $BMOD‘s non-invasive diagnostic tool, CyPath, is based on a patented porphyrin application, which binds to cancerous cells from lung samples.
$BMOD also has an agreement with Medical Acoustics, LLC to purchase its Lung Flute as part of the collection protocol in an upcoming clinical study.
Giving $BMOD even more potential, the company also has contracts with Quintiles Consulting and Alquest, Inc. for consultation and guidance related to the FDA approval process.
Earlier this month, $BMOD announced a collaboration with Amigenics for a variety of projects to advance technology for the early detection of lung and other cancers. Two weeks ago, this was followed by a strategic alliance with Obio, Inc. to expand $BMOD‘s cancer research in Ohio.
As if these developments aren’t enough to get people curious and excited about $BMOD, the company recently announced a private placement with LifeTech Capital for up to $2 million.
The Dean suggests that all of his students do their homework on this company because $BMOD could be making a move.
